Scribe Therapeutics files for IPO in test of public appetite for earlier-stage biotechs
Scribe Therapeutics seeks $75 million in an IPO, testing market appetite for early-stage biotech.
Velocity
How fast coverage is spreading — measured hourly from article rate × source diversity. How this works →
The brief
Scribe Therapeutics, an Alameda-based company specializing in gene-editing and cardiovascular disease treatments, has filed for a proposed initial public offering on the Nasdaq. The company aims to raise $75 million through the listing, with notable existing stockholders including Eli Lilly.
Coverage from Renaissance Capital, The Business Journals, and Investing.com highlights the firm's focus on cholesterol-fighting treatments and gene-editing technology. Endpoints News frames the filing as a significant test of public investor sentiment toward earlier-stage biotech companies.
Future coverage is expected to clarify the proposed share price range and the specific use of proceeds for the $75 million offering. Reports do not yet specify the ticker symbol or the timing of the IPO pricing.
Synthesized by PULSE from the headlines below under a strict no-invention contract. ✓ fact-checked: all claims supported by sources Updated 135d ago.
Quick answers
What is Scribe Therapeutics?
It is an Alameda-based biotech company focused on gene-editing and treatments for cardiovascular diseases and high cholesterol.
How much does the company plan to raise?
The company filed for a proposed $75 million IPO.
Who backs Scribe Therapeutics?
Current stockholders include Eli Lilly, though a full list of investors is not specified in the coverage.
Coverage (5)
- SCTX IPO News - Cardiovascular diseases biotech Scribe Therapeutics files for a $75 million IPO renaissancecapital.com · 138d ago
- Meet the gene-editing, cholesterol-fighting Alameda company looking for IPO riches The Business Journals · 138d ago
- Scribe Therapeutics files for proposed Nasdaq IPO By Investing.com Investing.com South Africa · 138d ago
- Scribe Therapeutics Stockholders Include Eli Lilly Moomoo · 138d ago
- Scribe Therapeutics files for IPO in test of public appetite for earlier-stage biotechs Endpoints News · 138d ago
Topics
Related trends
Anthropic’s IPO Is Igniting a Massive AI Wealth Boom in San Francisco
Anthropic's IPO at an expected $1.4 trillion valuation is igniting a massive AI wealth boom in San Francisco.
Dow falls 800 points as tech shares decline, traders eye reported NSA network outage: Live updates
U.S. equities tumbled Tuesday as the Dow fell hundreds of points, led by software and tech declines ahead of the Anthropic IPO.
Stock Market News: Global Stocks Downbeat Ahead of Nvidia Earnings
Global stocks turn downbeat as Wall Street focuses heavily on upcoming Nvidia earnings and executive shifts.
Biotech Tops The 'Most Bullish Conversations' And Breaks Out
Biotech markets surge in bullish conversations amid major trial outcomes and regulatory updates from key industry players.
This Anthropic proxy play is getting traders' attention
Multiple leveraged and inverse ETFs tied to Anthropic are set to launch this week, giving traders new ways to bet on the AI company's volatility.
Altimeter's Brad Gerstner aims to invest $5 billion in Anthropic IPO
Anthropic's anticipated IPO draws intense scrutiny as Brad Gerstner's Altimeter Capital signals a $5 billion investment interest amid questions over the AI firm's massive compute costs and governance structure.